亞洲 自體免疫與發炎藥物
自體免疫藥：讓攻擊自己身體的免疫系統冷靜下來。
8追蹤資產
6已核准
這個賽道在做什麼
乾癬、異位性皮膚炎、紅斑性狼瘡、類風濕性關節炎等自體免疫與發炎疾病，是免疫系統攻擊自己的組織。舊藥大範圍壓低免疫力；新藥只阻斷單一訊號，例如細胞內的 JAK、TYK2，或細胞外的 IL-4R、IL-17、BAFF／APRIL。中國在這個領域進展很快，多個中國原研的抗體與 JAK 抑制劑已在國內核准，國際藥廠也開始授權引進到海外市場。
階段分布
已核准6 6
第三期2 2
國家分布
日本2 2
中國6 6
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peficitinib (ASP015K; Smyraf) | peficitinib | Astellas Pharma Inc. | Japan | JAK family | Oral pan-JAK inhibitor | Approved — Japan (2019-03) | Rheumatoid arthritis | NCT02308163 | NCT02305849 | Menarini Asia-Pacific — Taiwan; option for select Southeast Asian markets | 2023-09-13 (announcement) | Not disclosed | €5.5 million (upfront + milestones; royalties additional) | Menarini announces Taiwan licensing agreement, with option for select Southeast Asian markets | 2023-09-13 | 1 2 3 4 5 | 2023-09-13 |
| 2 | Delgocitinib (JTE-052; Corectim / Anzupgo) | delgocitinib | Japan Tobacco Inc. | Japan | JAK family | Topical pan-JAK inhibitor | Approved — Japan (2020-01); US (2025-07) | Atopic dermatitis (Japan ointment); chronic hand eczema (US cream) | NCT05355818 | NCT06004050 | LEO Pharma — topical dermatology worldwide excluding Japan | 2014-11 | Not disclosed | Not disclosed | FDA approves Anzupgo cream for adult moderate-to-severe chronic hand eczema | 2025-07-23 | 1 2 3 4 5 6 | 2025-07-23 |
| 3 | Telitacicept (RC18; Taiai) | telitacicept | RemeGen Co., Ltd. | China | BAFF (BLyS); APRIL | TACI-Fc fusion protein inhibiting B-cell survival signals | Approved — China (2021-03; conditional); full approval 2023-11 | Systemic lupus erythematosus; rheumatoid arthritis; generalized myasthenia gravis | NCT03016013 | NCT05737160 | Vor Biopharma Inc. (Vor Bio) — worldwide excluding Greater China | 2025-06-25 | US$45 million cash + US$80 million warrants (US$125 million initial consideration) | US$125 million initial consideration + up to US$4,105 million milestones; royalties additional | RemeGen announces exclusive ex-Greater China license to Vor Bio | 2025-06-25 | 1 2 3 4 5 | 2025-06-25 |
| 4 | Vunakizumab (SHR-1314; Andajing) | vunakizumab | Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China | IL-17A | Humanized monoclonal antibody neutralizing IL-17A | Approved — China (2024-08) | Moderate-to-severe plaque psoriasis; active ankylosing spondylitis | NCT04839016 | None reported | — | — | — | Suzhou Industrial Park reports approval for active ankylosing spondylitis | 2025-05-07 | 1 2 3 4 | 2025-05-07 |
| 5 | Stapokibart (CM310; Kangyueda) | stapokibart | Keymed Biosciences Inc. | China | IL-4Rα | Humanized monoclonal antibody blocking IL-4 and IL-13 signaling via IL-4Rα | Approved — China (2024-09) | Atopic dermatitis; chronic rhinosinusitis with nasal polyps; seasonal allergic rhinitis | NCT05265923 | None reported | — | — | — | Company annual results report three approved stapokibart indications | 2025-03-26 | 1 2 3 4 | 2025-03-26 |
| 6 | Ivarmacitinib (SHR0302; Aisuda) | ivarmacitinib | Jiangsu Hengrui Pharmaceuticals Co., Ltd. / Reistone Biopharma | China | JAK1 | Selective JAK1 small-molecule inhibitor; oral and topical development | Approved — China (2025-03) | Active ankylosing spondylitis; rheumatoid arthritis; atopic dermatitis; severe alopecia areata | NCT04481139 | NCT05470413 | Arcutis — topical dermatology in US, Japan, UK, EU and Canada; ARQ-255 development halted | 2018-01 (option agreement); 2019-12 (license exercised) | US$0.4 million upfront + US$1.5 million option exercise | Up to US$20.5 million development/regulatory + US$200 million sales milestones; initial payments and royalties additional | Hengrui announces China approval for severe alopecia areata | 2025-06-30 | 1 2 3 4 5 6 | 2025-06-30 |
| 7 | Soficitinib (ICP-332) | soficitinib | InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd. | China | TYK2 (JH1) | Oral ATP-site TYK2 inhibitor | Phase 3 — China (2024-11) | Moderate-to-severe atopic dermatitis; other inflammatory skin diseases in earlier-stage trials | NCT06775860 | None reported | — | — | — | Company Q3 results report primary endpoints met in atopic dermatitis Phase 3 | 2026-10-26 | 1 2 3 4 | 2026-10-26 |
| 8 | Fadeucravacitinib (ICP-488) | fadeucravacitinib | InnoCare Pharma Limited / Beijing InnoCare Pharma Tech Co., Ltd. | China | TYK2 (JH2) | Oral allosteric TYK2 inhibitor | Phase 3 — China (2025-03) | Moderate-to-severe plaque psoriasis; cutaneous lupus and Sjögren syndrome in Phase 2 | NCT06842199 | None reported | — | — | — | Company Q3 results report primary endpoints met in psoriasis Phase 3 | 2026-10-26 | 1 2 3 4 | 2026-10-26 |